313 related articles for article (PubMed ID: 33294860)
1. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
2. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
Miao YR; Liu CJ; Hu H; Yang M; Guo AY
Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
[TBL] [Abstract][Full Text] [Related]
3. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS; Tsoi J; Onyshchenko M; Abril-Rodriguez G; Ross-Macdonald P; Wind-Rotolo M; Champhekar A; Medina E; Torrejon DY; Shin DS; Tran P; Kim YJ; Puig-Saus C; Campbell K; Vega-Crespo A; Quist M; Martignier C; Luke JJ; Wolchok JD; Johnson DB; Chmielowski B; Hodi FS; Bhatia S; Sharfman W; Urba WJ; Slingluff CL; Diab A; Haanen JBAG; Algarra SM; Pardoll DM; Anagnostou V; Topalian SL; Velculescu VE; Speiser DE; Kalbasi A; Ribas A
Cancer Cell; 2020 Oct; 38(4):500-515.e3. PubMed ID: 32916126
[TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract][Full Text] [Related]
5. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
Lim SY; Shklovskaya E; Lee JH; Pedersen B; Stewart A; Ming Z; Irvine M; Shivalingam B; Saw RPM; Menzies AM; Carlino MS; Scolyer RA; Long GV; Rizos H
Nat Commun; 2023 Mar; 14(1):1516. PubMed ID: 36934113
[TBL] [Abstract][Full Text] [Related]
6. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
Lau D; McLean MA; Priest AN; Gill AB; Scott F; Patterson I; Carmo B; Riemer F; Kaggie JD; Frary A; Milne D; Booth C; Lewis A; Sulikowski M; Brown L; Lapointe JM; Aloj L; Graves MJ; Brindle KM; Corrie PG; Gallagher FA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34561275
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
Front Immunol; 2020; 11():364. PubMed ID: 32194568
[TBL] [Abstract][Full Text] [Related]
10. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
11. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
12. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
[TBL] [Abstract][Full Text] [Related]
13. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
14. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
15. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
18. Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma.
Yang J; Zhao S; Wang J; Sheng Q; Liu Q; Shyr Y
J Genet Genomics; 2021 May; 48(5):361-368. PubMed ID: 34127402
[TBL] [Abstract][Full Text] [Related]
19. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.
Bagaev A; Kotlov N; Nomie K; Svekolkin V; Gafurov A; Isaeva O; Osokin N; Kozlov I; Frenkel F; Gancharova O; Almog N; Tsiper M; Ataullakhanov R; Fowler N
Cancer Cell; 2021 Jun; 39(6):845-865.e7. PubMed ID: 34019806
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
